These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25980499)

  • 21. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
    Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours.
    Dave F; Herrera K; Lockley A; van de Weijer LL; Henderson S; Sofela AA; Hook L; Adams CL; Ercolano E; Hilton DA; Maze EA; Kurian KM; Ammoun S; Hanemann CO
    Oncogene; 2024 Oct; 43(41):3049-3061. PubMed ID: 39179860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
    Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
    Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
    Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
    EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
    Zhu C; Wei Y; Wei X
    Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
    Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
    Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
    Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
    Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
    Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AXL regulates mesothelioma proliferation and invasiveness.
    Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
    Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
    Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
    J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
    Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
    Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
    Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma.
    Behrmann CA; Ennis KN; Sarma P; Wetzel C; Clark NA; Von Handorf KM; Vallabhapurapu S; Andreani C; Reigle J; Scaglioni PP; Meller J; Czyzyk-Krzeska MF; Kendler A; Qi X; Sarkaria JN; Medvedovic M; Sengupta S; Dasgupta B; Plas DR
    Cancer Res Commun; 2024 Aug; 4(8):2215-2227. PubMed ID: 39087397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction.
    Landolt L; Furriol J; Babickova J; Ahmed L; Eikrem Ø; Skogstrand T; Scherer A; Suliman S; Leh S; Lorens JB; Gausdal G; Marti HP; Osman T
    Physiol Rep; 2019 May; 7(10):e14091. PubMed ID: 31134766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
    Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
    Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.
    Wang X; Saso H; Iwamoto T; Xia W; Gong Y; Pusztai L; Woodward WA; Reuben JM; Warner SL; Bearss DJ; Hortobagyi GN; Hung MC; Ueno NT
    Cancer Res; 2013 Nov; 73(21):6516-25. PubMed ID: 24014597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.